Eurofins Scientific Se · EURONEXT:ERF
Eurofins Scientific — 9M 2025 Earnings Presentation
12 slides from Eurofins Scientific's earnings presentation, Oct 21, 2025
Slide 1: 9M 2025 Results Presentation
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2025. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: Key financial and operational highlights
Key financial and operational highlights Reported Revenues Key Highlights • Reported revenues in 9M 2025 totalled €5,415m, +5.3% vs 9M 2024, driven by organic growth and 9M 2025 Q3 2025 acquisitions, and despite a -1.5% headwind from foreign exchange and one fewer public working day • Organic revenu
Slide 4: Revenue bridge
Revenue bridge 5,415 (€m) 9M 2025: +4.0%1 Q3 2025: +4.2%1 • Negative FX effect in 9M (-1.5%) as the Euro strengthened against most currencies, broken down as: o Q1: +1.2% tailwind o Q2: -2.5% headwind o Q3: -3.0% headwind 5,215 • Organic revenue growth of 4.0%, (3.3% excluding adjustment for public
Slide 5: Organic growth by activity, 9M 2025
Organic growth by activity, 9M 2025 Revenues (€m) Commentary Organic growth1 +4.0% • Food and Feed Testing: continued performance across major regions, North America strengthened 5,415 further in Q3 5,142 Life • Environment Testing: good growth maintained in Europe year to date, North America remain
Slide 6: 31 acquisitions closed in 9M 2025
31 acquisitions closed in 9M 2025 to augment our technological capabilities and global footprint Acquired companies generated revenues of more than €250m in 2024 North America Europe Rest of the World 11 acquisitions 15 acquisitions 5 acquisitions Acquired: Acquired: Acquired: • Multiple bolt-on Env
Slide 7: Objectives confirmed for FY 2025
Objectives confirmed for FY 2025 Revenue • Mid-single-digit organic growth, and potential average revenues from acquisitions of €250m consolidated at mid-year EBITDA margin • Adj. EBITDA margin1 is expected to continue improving over the level in FY 2024 of 22.3% and SDI • SDI at the EBITDA level sh
Slide 8: Q&A
Q&A CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 8
Slide 9: Appendix
Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 9
Slide 10: Breakdown of revenue by Operating Segment
Breakdown of revenue by Operating Segment €m 9M 2025 As % of total 9M 2024 As % of total Y-o-Y variation Organic growth Europe 2,805 52% 2,620 51% 7.0% 2.7% North America 2,031 38% 1,974 38% 2.9% 2.9% Rest of the World 579 10% 547 11% 5.8% 8.1% Total 5,415 100% 5,142 100% 5.3% 3.3% €m Q3 2025 As % o
Slide 11: Breakdown of revenue by Area of Activity
Breakdown of revenue by Area of Activity €m 9M 2025 As % of total 9M 2024 As % of total Y-o-Y variation Organic growth Life 2,234 41% 2,093 41% 6.7% 6.2% BioPharma 1,544 29% 1,501 29% 2.9% 0.6% Diagnostic Services & Products 1,114 21% 1,025 20% 8.7% 2.0% Consumer & Technology Products Testing 523 10
Slide 12: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) Adjusted results – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. Separately disclosed items – include one-off costs from network expansion, integration and reorganisation, discontin